We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Innocoll Stock Gains on Favorable Phase III Data on Xaracoll
Read MoreHide Full Article
Shares of Innocoll Holdings plc surged 47.8% after the company announced positive data from two phase III studies – MATRIX-1 and MATRIX-2 – on Xaracoll (bupivacaine-collagen bioresorbable implant) for the treatment of postoperative pain relief.
The two identical, randomized, placebo-controlled, double-blinded studies evaluated the safety and efficacy of Xaracoll (300 mg dose) in the treatment of acute postoperative pain associated with hernia repair.
The studies met the primary endpoint, thereby demonstrating a statistically significant reduction in pain intensity over 24 hours after open abdominal hernia repair surgery. Xaracoll also showed consistency in treatment effect for both pain and opioid reduction. Moreover, the candidate was seen to be safe and generally well tolerated in both the studies, with no Xaracoll-related serious adverse events.
Full analysis of the MATRIX studies will be presented at future medical conferences and submitted for publication.
Innocoll plans to submit a New Drug Application (NDA) for Xaracoll in the U.S. in the third or early fourth quarter of 2016 and expects to launch the product in 2017.
According to Innocoll, the postoperative pain relief market presently has significant unmet need, with long-acting anesthetics comprising only 5%. The company believes that Xaracoll has an addressable market worth approximately $6 billion in the U.S.
Meanwhile, data from phase III studies on Xaracoll also validated the company’s collagen-based technology platform. Another candidate in Innocoll’s pipeline, Cogenzia, is being evaluated in phase III studies (COACT-1 and COACT-2) for the treatment of diabetic foot infections. Top-line data from the studies are anticipated later in 2016.
Currently, Innocoll carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Bristol-Myers Squibb Company (BMY - Free Report) , ANI Pharmaceuticals, Inc. (ANIP - Free Report) and Pfizer Inc. (PFE - Free Report) , each sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Innocoll Stock Gains on Favorable Phase III Data on Xaracoll
Shares of Innocoll Holdings plc surged 47.8% after the company announced positive data from two phase III studies – MATRIX-1 and MATRIX-2 – on Xaracoll (bupivacaine-collagen bioresorbable implant) for the treatment of postoperative pain relief.
The two identical, randomized, placebo-controlled, double-blinded studies evaluated the safety and efficacy of Xaracoll (300 mg dose) in the treatment of acute postoperative pain associated with hernia repair.
The studies met the primary endpoint, thereby demonstrating a statistically significant reduction in pain intensity over 24 hours after open abdominal hernia repair surgery. Xaracoll also showed consistency in treatment effect for both pain and opioid reduction. Moreover, the candidate was seen to be safe and generally well tolerated in both the studies, with no Xaracoll-related serious adverse events.
Full analysis of the MATRIX studies will be presented at future medical conferences and submitted for publication.
Innocoll plans to submit a New Drug Application (NDA) for Xaracoll in the U.S. in the third or early fourth quarter of 2016 and expects to launch the product in 2017.
According to Innocoll, the postoperative pain relief market presently has significant unmet need, with long-acting anesthetics comprising only 5%. The company believes that Xaracoll has an addressable market worth approximately $6 billion in the U.S.
Meanwhile, data from phase III studies on Xaracoll also validated the company’s collagen-based technology platform. Another candidate in Innocoll’s pipeline, Cogenzia, is being evaluated in phase III studies (COACT-1 and COACT-2) for the treatment of diabetic foot infections. Top-line data from the studies are anticipated later in 2016.
Currently, Innocoll carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Bristol-Myers Squibb Company (BMY - Free Report) , ANI Pharmaceuticals, Inc. (ANIP - Free Report) and Pfizer Inc. (PFE - Free Report) , each sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>